Libório H, Borges T, Pereira M, Ross W, Fernandes J-C, Fernandes G-V, Leitão-Almeida B
1500 Park Ave., St. Louis 63104, MO, U.S.A.
Med Oral Patol Oral Cir Bucal. 2025 Jan 1;30(1):e86-e96. doi: 10.4317/medoral.26842.
Extraction of impacted third molars is a standard procedure in dentistry. However, the postoperative inflammation and pain are undesired and uncomfortable. Methylprednisolone has emerged as a possible solution to improve outcomes. This systematic review aimed to evaluate methylprednisolone in the postoperative period of impacted third molars in relation to its efficacy in postoperative pain and edema, dosage regimens, administration forms, and adverse effects.
Following the PRISMA guidelines, the focus question was: "In patients who underwent impacted third molar extraction, what was the effect of methylprednisolone used postoperatively compared to non-use or the use of other medications within the same pharmacotherapeutic group to reduce inflammation and pain?" PubMed/MEDLINE and Scopus were consulted, and an additional manual was performed. The search included articles published in the last 10 years, with the language restriction to English. The articles were analyzed using the PRISMA principles, with pre-defined eligibility criteria. The data were extracted based on the general necessary information. The risk of bias for the RCTs included was performed using a revised Cochrane risk-of-bias tool for randomized trials, and a meta-analysis was performed.
Nine articles were included, and five were quantitatively analyzed. Evaluating the test and control groups (methylprednisolone versus controls), there was no significant heterogeneity for pain at 24 hours (p=0.15, I²=47%) and 7 days (p=0.15, I²=47%), with non-significant effects (p=0.85). In the inter-incisal reduction, there was homogeneity at 48 hours (p=0.96, I²=0%) and 7 days (p=0.37, I²=0%), with a greater reduction in the methylprednisolone group (p<0.01 and p<0.05, respectively).
Methylprednisolone is efficient in safely treating patients after third molar extraction, reducing pain, edema, and trismus. It achieved better results for the inter-incisal level than dexamethasone; otherwise, dexamethasone is preferable in minimizing postoperative trismus, presenting superior potential in this specific clinical context.
拔除阻生第三磨牙是牙科的一项标准操作。然而,术后炎症和疼痛是令人不适的。甲基泼尼松龙已成为一种可能改善预后的解决方案。本系统评价旨在评估甲基泼尼松龙在阻生第三磨牙术后的疗效,包括术后疼痛和水肿、给药方案、给药形式及不良反应。
遵循PRISMA指南,核心问题为:“在接受阻生第三磨牙拔除术的患者中,与未使用甲基泼尼松龙或在同一药物治疗组中使用其他药物相比,术后使用甲基泼尼松龙对减轻炎症和疼痛有何效果?”检索了PubMed/MEDLINE和Scopus,并进行了额外的手工检索。检索纳入过去10年发表的文章,语言限制为英文。根据预定义的纳入标准,使用PRISMA原则对文章进行分析。基于一般必要信息提取数据。对纳入的随机对照试验使用修订后的Cochrane随机试验偏倚风险工具进行偏倚风险评估,并进行荟萃分析。
纳入9篇文章,其中5篇进行了定量分析。评估试验组和对照组(甲基泼尼松龙组与对照组),术后24小时(p = 0.15,I² = 47%)和7天(p = 0.15,I² = 47%)疼痛方面无显著异质性,效果不显著(p = 0.85)。在切牙间距离减小方面,术后48小时(p = 0.96,I² = 0%)和7天(p = 0.37,I² = 0%)具有同质性,甲基泼尼松龙组减小更明显(分别为p < 0.01和p < 0.05)。
甲基泼尼松龙能有效安全地治疗第三磨牙拔除术后的患者,减轻疼痛、水肿和牙关紧闭。在切牙间水平上,其效果优于地塞米松;否则,地塞米松在使术后牙关紧闭最小化方面更可取,在这一特定临床背景下具有更大优势。